Anticancer therapeutic agents
The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.
1. A method of reducing cellular proliferation of breast cancer, pancreatic cancer, or neuroblastoma cancer cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable salt thereof.
2. A method for reducing cellular proliferation of breast cancer, pancreatic cancer, or neuroblastoma cancer cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) comprising administering a therapeutically effective amount of a compound of the formula
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a compound of the formula
or a pharmaceutically acceptable salt thereof, and further comprising one or more carriers, diluents, or excipients.
4. The method of claim 1 , wherein administration of said compound augments another chemotherapeutic method.
5. A pharmaceutical composition according to claim 3 , further comprising a second chemotherapeutic agent.